Survival analysis demonstrated that AML patients with a high level of expression of GLI1, PIK3R1, and AKT3 had shorter overall survival (Kaplan–Meier survival analysis) (Figs. 1D and S1B). The gene discussed is AKT3; the disease is acute myeloid leukemia.